Double-stranded RNA (dsRNA) is a major impurity of therapeutic mRNA produced by in vitro transcription. Impurity levels of this transcriptional by-product need to be tightly monitored in mRNA production lots to ensure efficient mRNA expression and to reduce the risk of undesired high immunogenicity[1-2].
Dot blot assays using SCICONS’s Anti-dsRNA monoclonal antibody J2 are a fast and easy method for the detection of dsRNA in both crude in vitro transcription mixes as well as purified mRNA[1-6]. Estimation of the amount of dsRNA impurity is feasible with a dsRNA control run in parallel (Fig. 1).